NC H652

Establishes the Right to Try Act allowing terminally ill patients to access investigational drugs, biological products, and devices that have completed Phase I clinical trials but lack FDA approval.

Requires eligible patients to have a terminal illness diagnosis, consider all FDA-approved treatments, receive physician recommendation, and provide written informed consent detailing risks, benefits, and financial liability.

Prohibits state licensing boards and Medicare from disciplining health care providers solely for recommending investigational treatments to eligible patients.

Prevents state officials from blocking eligible patients' access to investigational treatments and shields manufacturers from liability for harm caused by investigational drugs or devices if they exercise reasonable care and good faith efforts.

Takes effect October 1, 2015.